TMRW Life Sciences Acquires Cryogatt Patent Portfolio to Expand Digital Specimen Management Solutions and Sperm Storage Offerings

NEW YORK, June 10, 2025 /PRNewswire/ -- TMRW Life Sciences, the fertility technology company transforming how frozen eggs, embryos, and sperm are stored and managed, today announced the acquisition of Cryogatt Systems' patent portfolio, which includes RFID methodologies for cryogenic storage systems equipped with integrated sensor and tracking technologies.

This strategic acquisition supports TMRW's continued investment and innovation in digital specimen management and state-of-the-art cryostorage. Building on this newly acquired technology, TMRW plans to introduce a more robust digital solution for non-TMRW storage tanks and expanded sperm storage offerings—extending its trusted safety, traceability, and efficiency.

"These patents help lay the foundation for the next generation of TMRW's digital solutions," said Cynthia Hudson, Head of Clinical Strategy at TMRW Life Sciences. "We're continuing to expand our product offering to support each fertility clinic's unique needs—whether they're upgrading existing infrastructure or seeking new ways to modernize their specimen storage."

The acquired RFID-based technology will serve as the building blocks for:

• An expanded digitally integrated sperm storage solution, bringing TMRW's safety, traceability, and security to additional sperm cryostorage offerings
• Enhanced digital management for non-TMRW tanks, allowing clinics to extend key benefits of TMRW's ecosystem without replacing their existing storage systems
• A more robust digital audit trail for select storage solutions, increasing transparency and accountability in specimen management

Incorporating these innovations allows TMRW to continue advancing and raising the standard of care in IVF cryostorage. TMRW already seamlessly integrates with partner clinics' EMR systems and is fully compatible with all commercially available laboratory electronic witnessing systems—enabling automatic data capture, eliminating double data entry, and reducing the risk for human error.

"As demand for fertility treatments continues to grow, clinics need solutions that are not only scalable but also raise the standard of care," said Louis Villalba, CEO of TMRW Life Sciences. "This acquisition reflects our commitment to continued innovation and to supporting clinics with technology that goes beyond what's required today. We're focused on helping the industry meet this moment—and what comes next."

The corporate team at Penningtons Manches Cooper LLP, led by Matthew Martin, Global Head of Corporate and with support from Associate, Emily MacDonald, advised on the UK legal aspects of this deal on behalf of the joint liquidators of Cryogatt Systems Limited, Laurence Pagden and Giuseppe Parla of Menzies LLP.

About TMRW Life Sciences
Founded in 2018, TMRW Life Sciences, Inc., is a fertility technology company digitizing the IVF lab starting with the world's first automated platform for the safe management and storage of frozen sperm, eggs and embryos. For the first time, frozen specimens can be digitally identified and tracked, safely managed with automated robotics, and remotely monitored around the clock. TMRW's next-generation technology platforms set a new standard of care, reducing potential points of failure by 94% compared to manual systems. TMRW delivers peace of mind by helping reduce the risk of specimen mix-up, damage, or loss. Named Fast Company's #1 Most Innovative Biotech company in 2022, TMRW has been adopted by leading clinics across the United States and United Kingdom.

SOURCE TMRW Life Sciences